Anavex Life Sciences Corp (AVXL)

[LBSR TO DA MOON]

Not quite sure how anyone can argue with your statement below. It certainly seems reasonable to me. Approval of A2-73 for Rett (both adult and pediatric) and the issuance of the voucher (possible value in excess of $100M) within the next 12 months? I'll take it! Of course, any earlier surprises would be more than welcomed...

An obvious way of putting any doubt to bed would be to wait for data from the much larger EXCELLENCE trial and look for even better response grouped by age and using the exact same primary CGI-I Anchored RSBQ AUC endpoint measure. Those score being well excellent in a 3rd parallel trial should put any statistical, clinical meaningfulness and questionnaire based scoring reliability concerns to bed and lead to approval of A2-73 for Rett in all age and the issuance of a the paediatric voucher.